https://hipa.ai/drug/pembrolizumab/updates/trial-results-posted-nct05491317-2026-07-02 Hipa.ai en 2026-07-02T00:00:00.000Z Pembrolizumab Combo Shows 14.3% ORR in Metastatic Solid Tumors Trial https://hipa.ai/drug/dapagliflozin/updates/indication-usage-updated-dapagliflozin-label-effective-2026-2026-07-02 Hipa.ai en 2026-07-02T00:00:00.000Z Dapagliflozin Label Updated for Heart Failure Risk Reduction in T2DM https://hipa.ai/drug/nivolumab/updates/trial-results-posted-nct04401995-2026-07-02 Hipa.ai en 2026-07-02T00:00:00.000Z Nivolumab with Vidutolimod shows higher pathologic response in Melanoma https://hipa.ai/drug/canagliflozin/updates/boxed-warning-revised-metformin-hydrochloride-label-2026-07-01 Hipa.ai en 2026-07-01T00:00:00.000Z Metformin Hydrochloride Boxed Warning Revised for Lactic Acidosis Risk https://hipa.ai/drug/canagliflozin/updates/boxed-warning-revised-metformin-hydrochloride-er-label-2026-07-01 Hipa.ai en 2026-07-01T00:00:00.000Z Metformin Hydrochloride ER Boxed Warning Revised for Lactic Acidosis https://hipa.ai/drug/adalimumab/updates/boxed-warning-present-label-yuflyma-label-effective-2026-07-2026-07-01 Hipa.ai en 2026-07-01T00:00:00.000Z Adalimumab (Yuflyma) Label Adds Boxed Warning for Serious Infections and… https://hipa.ai/drug/pembrolizumab/updates/trial-results-posted-nct04924101-2026-07-01 Hipa.ai en 2026-07-01T00:00:00.000Z Pembrolizumab + Lenvatinib + Chemo Shows 73.7% ORR in ES-SCLC Trial https://hipa.ai/drug/pembrolizumab/updates/trial-results-posted-nct04788043-2026-06-30 Hipa.ai en 2026-06-30T00:00:00.000Z Pembrolizumab/Magrolimab Trial for Relapsed Hodgkin Lymphoma Terminated https://hipa.ai/drug/pembrolizumab/updates/trial-results-posted-nct03924895-2026-06-30 Hipa.ai en 2026-06-30T00:00:00.000Z Pembrolizumab + Enfortumab Vedotin Combo Boosts Bladder Cancer pCR, pDS https://hipa.ai/drug/lecanemab/updates/boxed-warning-present-label-leqembi-label-effective-2026-06-2026-06-30 Hipa.ai en 2026-06-30T00:00:00.000Z Lecanemab (LEQEMBI) Label Adds Boxed Warning for ARIA Risks https://hipa.ai/drug/orforglipron/updates/trial-results-posted-nct06010004-2026-06-30 Hipa.ai en 2026-06-30T00:00:00.000Z Orforglipron Phase 3 Trial in Type 2 Diabetes Shows Significant HbA1c Lowering